Mycosyst-Gyno (Fluconazole)

Fluconazole is an azole antifungal that targets Candida species across a range of mucosal and systemic infections.

• Vulvovaginal candidiasis: effective relief of itching, discharge and irritation caused by Candida infection.
• Oropharyngeal candidiasis: eradicates yeast overgrowth in the mouth and throat.
• Esophageal candidiasis: resolves fungal infection of the esophagus, improving swallowing.
• Cryptococcal meningitis: used as part of combination therapy to treat fungal meningitis.
• Systemic candidiasis: treats invasive Candida infections affecting blood and organs.

• Fluconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By blocking this enzyme, the drug disrupts the formation of ergosterol, an essential component of the fungal cell membrane, leading to increased membrane permeability and ultimately fungal cell death. The selective inhibition results in minimal impact on human cells, allowing oral administration with systemic exposure.

Fluconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset or queasiness.
• Headache: transient head pain.
• Diarrhea: loose stools.
• Abdominal pain: cramping or discomfort.
• Rash: skin redness or mild itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmias: QT interval prolongation.
• Anaphylaxis: rare allergic shock.
• Hematologic abnormalities: neutropenia or thrombocytopenia.

When prescribing fluconazole, clinicians should consider several precautionary measures to ensure safe use.

• Liver function: assess hepatic status before initiating therapy and monitor during treatment.
• Renal impairment: adjust dose in patients with severe kidney dysfunction.
• Pregnancy: avoid unless benefit outweighs potential risk, as safety data are limited.
• Concomitant QT‑prolonging drugs: monitor cardiac rhythm when combined.
• Drug interactions: review concurrent medications for CYP450 interactions.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Fluconazole interacts with several medicines through cytochrome P450 pathways and other mechanisms.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic fluconazole levels.
• CYP2C9 substrates (e.g., warfarin): increased anticoagulant effect, risk of bleeding.
• Certain antiretrovirals (e.g., protease inhibitors): may lead to serious toxicity.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: reduced efficacy, consider backup contraception.
• Statins (e.g., simvastatin): increased risk of myopathy, monitor muscle symptoms.
• Phenytoin: decreased fluconazole concentrations, may reduce efficacy.